Retinopathy of prematurity (ROP) is a vasoproliferative retinal disease that afflicts as much as 50% of all extremely low gestational age neonates (ELGANs, <1250g/<28 weeks) with approximately 5% condemned to a lifetime of blindness. Caffeine and NSAIDs have been shown to decrease the risk of severe ROP in ELGANs. However, the routes of administration and the timing of drug intervention remain debatable. We propose a novel approach combining topical ibuprofen or ketorolac with systemic caffeine to optimize their efficacy for prevention of oxygen-induced retinopathy (OIR). The overarching goal of this proposal is to investigate whether topical ocular ibuprofen or ketorolac potentiated with systemic caffeine decreases the incidence and/or severity of OIR in neonatal rats exposed to frequent, brief, clustered hyperoxia-hypoxia cycling.
Our specific aims are three-fold: 1) To identify the critical number of hyperoxic/hypoxic episodes that will result in upregulation of genes responsible for abnormal angiogenesis and severe OIR. We hypothesize that there is a critical number of hyperoxia/hypoxia cycles beyond which the developing retina will not recover;2) Using optimized preparations, we will determine if ibuprofen (Neoprofen) or a new preparation of ketorolac (Acuvail) administered topically as eye drops, with or without systemic caffeine citrate (Cafcit) exert protective effects on the retina at risk for severe OIR. We will also determine the dose-response of ibuprofen. We hypothesize that topical ibuprofen or ketotolac potentiated with systemic caffeine will provide long term efficacy and safety for prevention of OIR;and 3) To examine whether the protective effects of ibuprofen or ketorolac eye drops, potentiated with caffeine, are determined by timing of administration of the drug. We hypothesize that timing of drug administration in relation to the disease phase (vasoobliterative versus proliferative) is a major determinant of drug efficacy. We believe that once activated in the immature retina, the mechanisms for neovascularization are irreversible. Early identification and prevention is vital. Our proposed studies will aid in early identification of infants at risk.

Public Health Relevance

These proposed studies will use topical, non-invasive, NSAIDs (ibuprofen and ketorolac) complemented with systemic caffeine citrate to preserve normal retinal growth and development during oxidative stress in order to protect the immature retina. Data from these studies will form the rationale for a future clinical trial to prevent ROP, the most common cause of childhood blindness. ROP is the leading cause of childhood blindness and the epidemic is increasing. Current medications, such as intravitreal Avastin is highly invasive, causes retinal hemorrhage, retinal detachment, choroidal ruptures, etc., and may have adverse effects on associated retinal cells such as astrocyges and microglia. The need for other potential therapies is vital. The unique strategy proposed in these studies will provide an alternate approach and form the rationale for a future clinical trial.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54HD071594-03
Application #
8473238
Study Section
Special Emphasis Panel (ZHD1-DSR-A)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
3
Fiscal Year
2013
Total Cost
$139,971
Indirect Cost
$52,216
Name
Suny Downstate Medical Center
Department
Type
DUNS #
040796328
City
Brooklyn
State
NY
Country
United States
Zip Code
11203
Wang, Xue; Niu, Jin; Li, Jun et al. (2018) Temporal Effects of Combined Birinapant and Paclitaxel on Pancreatic Cancer Cells Investigated via Large-Scale, Ion-Current-Based Quantitative Proteomics (IonStar). Mol Cell Proteomics 17:655-671
Beharry, Kay D; Cai, Charles L; Skelton, Jacqueline et al. (2018) Oxygen-Induced Retinopathy from Recurrent Intermittent Hypoxia Is Not Dependent on Resolution with Room Air or Oxygen, in Neonatal Rats. Int J Mol Sci 19:
Beharry, Kay D; Cai, Charles L; Ahmad, Taimur et al. (2018) Impact of Chronic Neonatal Intermittent Hypoxia on Severity of Retinal Damage in a Rat Model of Oxygen-Induced Retinopathy. J Nat Sci 4:
Nicolau, Yona; Bany-Mohammed, Fayez; Cai, Charles L et al. (2018) SiRNA silencing of VEGF, IGFs, and their receptors in human retinal microvascular endothelial cells. Am J Transl Res 10:1990-2003
Cai, Charles; Ahmad, Taimur; Valencia, Gloria B et al. (2018) Intermittent hypoxia suppression of growth hormone and insulin-like growth factor-I in the neonatal rat liver. Growth Horm IGF Res 41:54-63
Valencia, Arwin M; Abrantes, Maria A; Hasan, Jamal et al. (2018) Reactive Oxygen Species, Biomarkers of Microvascular Maturation and Alveolarization, and Antioxidants in Oxidative Lung Injury. React Oxyg Species (Apex) 6:373-388
Beharry, Kay D; Cai, Charles L; Valencia, Gloria B et al. (2018) Human retinal endothelial cells and astrocytes cultured on 3-D scaffolds for ocular drug discovery and development. Prostaglandins Other Lipid Mediat 134:93-107
Quan, Michelle; Cai, Charles L; Valencia, Gloria B et al. (2017) MnTBAP or Catalase Is More Protective against Oxidative Stress in Human Retinal Endothelial Cells Exposed to Intermittent Hypoxia than Their Co-Administration (EUK-134). React Oxyg Species (Apex) 3:47-65
Shen, Xiaomeng; Shen, Shichen; Li, Jun et al. (2017) An IonStar Experimental Strategy for MS1 Ion Current-Based Quantification Using Ultrahigh-Field Orbitrap: Reproducible, In-Depth, and Accurate Protein Measurement in Large Cohorts. J Proteome Res 16:2445-2456
Valencia, Arwin M; Cai, Charles L; Tan, Jeffrey et al. (2017) Intravitreal bevacizumab alters type IV collagenases and exacerbates arrested alveologenesis in the neonatal rat lungs. Exp Lung Res 43:120-133

Showing the most recent 10 out of 52 publications